Clinical Trials
9 trialsNCT01046825 2026-06-02
Mature B-Cell Lymphoma And Leukemia Study III
St. Jude Children's Research Hospital
Phase 2/3 Active not recruiting
NCT04745910 2026-05-06
Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 4 Completed
NCT00199043 2023-03-17
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Goethe University
Phase 3 Completed
NCT01200485 2020-01-31
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01564277 2018-01-09
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00513474 2017-05-25
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT00186940 2017-04-25
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
St. Jude Children's Research Hospital
Completed
NCT00628628 2013-08-01
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00360438 2012-08-01
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
M.D. Anderson Cancer Center
Phase 1/2 Completed